Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Our Editorial Board

Editor's pick

17-08-2018 | Cervical cancer | News

Catch-up HPV vaccination supported in older adolescence

US researchers have found evidence to support catch-up vaccination against the human papillomavirus in women given their first dose in older adolescence.

26-07-2018 | Non-small cell lung cancer | Editorial | Article

Choosing an immunotherapy approach in patients with advanced non-small-cell lung cancer

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

06-07-2018 | Prostate cancer | Editorial | Article

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Specialty

Latest from across the site

17-08-2018 | Cervical cancer | News

Catch-up HPV vaccination supported in older adolescence

US researchers have found evidence to support catch-up vaccination against the human papillomavirus in women given their first dose in older adolescence.

Source:

Lancet Child Adolesc Health 2018; doi:10.1016/S2352-4642(18)30220-7
Lancet Child Adolesc Health 2018; doi: 10.1016/S2352-4642(18)30268-2

16-08-2018 | Skin cancers | News

Brief dermatologist-delivered intervention may improve sun protection behavior

The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.

Source:

JAMA Dermatol 2018; doi:10.1001/jamadermatol.2018.2331

15-08-2018 | Ovarian cancer | News

Apatinib–etoposide shows promise in platinum-resistant ovarian cancer

Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30349-8
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30444-3

14-08-2018 | Hepatocellular carcinoma | News

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

Source:

JAMA Surg 2018; doi:10.1001/jamasurg.2018.2721
JAMA Surg 2018; doi:10.1001/jamasurg.2018.2728

14-08-2018 | Recurrence | News

TNF inhibitors may not increase cancer recurrence risk

Patients with a history of cancer who receive tumor necrosis factor inhibitors for rheumatoid arthritis may not be at increased risk for recurrence, suggests a Swedish population-based study.

Source:

Ann Intern Med 2018; doi:10.7326/M17-2812

13-08-2018 | Waldenström macroglobulinemia | News

Ibrutinib monotherapy promising for untreated Waldenström macroglobulinemia

Phase II trial results suggest that the Bruton tyrosine kinase inhibitor ibrutinib has high activity and is well tolerated in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6426
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.3273

Scientific summary

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

This program was made possible thanks to independent educational sponsorship from MorphoSys.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

image credits